Methylcitric acid is an organic acid measured in urine as part of metabolic profiling. Biochemically, it arises when propionyl-CoA is condensed with oxaloacetate to form methylcitrate; this pathway becomes more active when normal propionate-processing enzymes are slowed or overloaded. Clinically, methylcitric acid has been used for decades in organic acid testing to flag altered propionate and odd‑chain fatty acid handling. Biotin functions as a cofactor for several carboxylases that help process propionyl-CoA and related substrates. Because those enzymes rely on biotin for proper activity, patterns in methylcitric acid—especially alongside related organic acids—can help identify functional bottlenecks in intermediary metabolism and guide further evaluation of metabolic balance.

Elevated methylcitric acid is commonly associated with impaired clearance of propionate-related metabolites. This pattern can reflect reduced activity of biotin-dependent carboxylases, excess substrate from odd‑chain fats or certain amino acids, or increased propionate production from gut microbes. Interpretation is most informative when compared with other organic acids (for example, propionylglycine, 3‑hydroxypropionate, and methylmalonic acid) and clinical context. Low or typical methylcitric acid levels generally suggest that propionate handling is not generating a detectable methylcitrate load. Isolated low values are often of limited concern; meaningful conclusions depend on the full panel of metabolic, oxidative, and genetic markers provided by the Cellular Zoomer.

The Cellular Zoomer includes methylcitric acid to assess how effectively cells manage propionate-derived substrates and to flag potential strain on biotin-dependent carboxylases. As part of the integrated organic acid and redox profile, it helps pinpoint metabolic bottlenecks and informs targeted follow-up and personalized clinical interpretation.